ArticleAMB Express2026
Protective effects of Curcumin-Zinc complex on inflammatory damage of IPEC-J2 cells induced by bacterial lipopolysaccharide.
Article in AMB Express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Curcumin as a Green Antibiotic Substitute: Mechanisms and Applications in Poultry Production and Health Promotion.Animals : an open access journal from MDPI · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The present study aimed to investigate the potential mitigative effects of the Curcumin-Zinc Complex (Cur-Zn) on bacterial lipopolysaccharide (LPS)-induced inflammatory damage in porcine small intestinal epithelial cells (IPEC-J2). IPEC-J2 cells were initially assigned to one of six treatment groups for 24 h (N = 6): the control group (0 µM Cur-Zn and 0 µg.mL− 1 LPS), the LPS group (0 µM Cur-Zn and 1 µg.mL− 1 LPS), and four cotreatment groups receiving varying concentrations of Cur-Zn (5, 10, 20, and 40 µM, respectively) combined with a constant LPS concentration (1 µg.mL− 1). Cell viability, apoptosis rate, and lactate dehydrogenase (LDH) level were detected. The results showed that 20 µM or 40 µM Cur-Zn significantly increased cell viability and significantly decreased apoptosis rate and LDH release in IPEC-J2 cells challenged with LPS, so 20 µM Cur-Zn was adopted for the mechanistic assays. Then, IPEC-J2 cells were randomly assigned to one of three treatment groups for 24 h (N = 6): the control group (CON; 0 µM Cur-Zn and 0 µg.mL− 1 LPS), the LPS group (LPS; 0 µM Cur-Zn and 1 µg.mL− 1 LPS), and Cur-Zn and LPS co-treated groups (Cur-Zn + LPS; 20 µM Cur-Zn and 1 µg.mL− 1 LPS). The results indicated that Cur-Zn treatment significantly increased the genes and proteins expression of zonula occluden-1 (ZO-1), Claudin-1, Occludin, and mucin 2 (MUC2), and significantly decreased the gene and protein expression of Caspase 3 in LPS-induced IPEC-J2 cells. Treatment of LPS-stimulated IPEC-J2 cells with Cur-Zn significantly reduced nitric oxide (NO), interleukin (IL)-1β, IL-6 and tumor necrosis factor α (TNF-α) production, and decreased the genes and proteins expression of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88) and nuclear factor-κB (NF-κB). Furthermore, Cur-Zn increased the production of anti-inflammatory cytokine IL-13 in LPS-challenged IPEC-J2 cells. It provides preliminary evidence that Cur-Zn may alleviate inflammatory responses by inhibiting the TLR4/ NF-κB signaling pathway. In conclusion, Cur-Zn can mitigate the inflammatory damage induced by LPS stimulation in IPEC-J2 cells by enhancing barrier and immune functions while reducing the inflammatory response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.